BridgeMD
New treatment option for Chronic Pain
Official title Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
ClinicalTrials.gov ID: NCT04939623
What this study is testing
What is Probenecid?
Probenecid is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for chronic pain.
Also referred to as 4-(Dipropylsulfamoyl)benzoic acid, Benemid.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The proposed clinical trial will address the problem of opioid withdrawal. Opioids are essential for pain-relief in the short term, but their continued use is associated with a host of adverse effects.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Adults with chronic pain. Age greater than or equal to 18 years on the day of enrolment.
- people are currently taking a daily opioid pain medication and planning to taper the dose.
- Participants complete at least one voluntary opioid dose reduction in the twelve-week study period.
- Glomerular filtration rate (GFR) \> 50 mL/min
- Capable of providing informed consent
You likely can't join if
- Allergy to probenecid or related drugs
- History of uric acid renal calculi, if known to be urate calculi. If unknown type, then any history of renal calculi.
- Known G6PD deficiency
- Active gout in any joint
- Current use of drugs whose exposure may be prolonged, or risk of toxicity increased when used in combination with probenecid:
- Penicillins, specifically ampicillin, penicillin G sodium, and piperacillin
See the full eligibility criteria
- Adults with chronic pain. Age greater than or equal to 18 years on the day of enrolment.
- people are currently taking a daily opioid pain medication and planning to taper the dose.
- Participants complete at least one voluntary opioid dose reduction in the twelve-week study period.
- Glomerular filtration rate (GFR) \> 50 mL/min
- Capable of providing informed consent
- Allergy to probenecid or related drugs
- History of uric acid renal calculi, if known to be urate calculi. If unknown type, then any history of renal calculi.
- Known G6PD deficiency
- Active gout in any joint
- Current use of drugs whose exposure may be prolonged, or risk of toxicity increased when used in combination with probenecid:
- Penicillins, specifically ampicillin, penicillin G sodium, and piperacillin
- Carbapenems, specifically doripenem and meropenem
- Lorazepam, midazolam, nitrazepam
- Ketorolac
- Oseltamivir
- Methotrexate
- Mycophenolate
- Current use of drugs which may mask symptoms of withdrawal: a. Clonidine, lofexidine, tizanidine
- Current use of drugs which may diminish the effect of probenecid: a. High dose salicylates including greater than 325 mg PO daily of acetylsalicylic acid (ASA)
- Pregnancy or breastfeeding
- Any major comorbid medical condition which might impair follow-up or result in a safety risk to the participant
- Participation in another clinical trial investigating a drug, medical device, or a medical procedure during the 30 days prior to enrolment. \-
The study team makes the final eligibility decision.
Where it's taking place
- Calgary, Alberta, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Calgary, Alberta, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.